Evolent Health (EVH) Cash & Current Investments (2015 - 2026)

Evolent Health's Cash & Current Investments history runs 12 years deep, the most recent figure standing at $166.0 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 40.26% year-over-year to $166.0 million in Q1 2026; TTM through Mar 2026 was $166.0 million, a 40.26% decrease from a year earlier, with the FY2025 full-year figure at $178.0 million, up 8.86% from the prior year.
• Cash & Current Investments slipped to $166.0 million in Q1 2026 per EVH's latest filing, from $178.0 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $280.4 million in Q2 2022 and bottomed at $127.9 million in Q3 2024.
• The 5-year median for Cash & Current Investments is $194.8 million (2022), against an average of $199.1 million.
• Across the five-year window, Cash & Current Investments tumbled 43.05% in 2024 and rose 27.13% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $215.2 million in 2022, then fell by 3.98% to $206.6 million in 2023, then declined by 20.86% to $163.5 million in 2024, then increased by 8.86% to $178.0 million in 2025, then fell by 6.75% to $166.0 million in 2026.
• Per Business Quant, the three latest EVH Cash & Current Investments figures stand at $166.0 million (Q1 2026), $178.0 million (Q4 2025), and $140.4 million (Q3 2025).